Agilent Technologies and Exelixis sign agreement for customized DNA microarrays

18-Oct-2000

Agilent Technologies Inc. (NYSE: A) announced that it has entered into an agreement to supply customizable DNA microarrays to Exelixis Inc. (Nasdaq: EXEL), a leader in the fields of model system genetics and comparative genomics. Exelixis will use Agilent's flexible microarray platform for Expression profiling experiments in various model organisms to supplement existing Exelixis platforms for high-throughput functional genomics analysis. Financial details of the agreement were not disclosed.

"We are pleased to have Exelixis, a pioneer in the field of comparative genomics, select Agilent's microarrays as research tools to perform high-throughput gene expression profiling analysis," said Bill Buffington, vice president of Agilent's Life Sciences Business Unit. "As a leading provider of customized microarray solutions, consulting services, informatics software and tools for gene expression analysis, Agilent is well placed to help Exelixis identify those key pathways associated with diseases or biologies."

"The Agilent technology provides another tool in our powerful array of integrated genetics and genomics technologies," said Geoffrey Duyk, M.D., Ph.D., chief scientific officer of Exelixis Inc. "We can use the expression profiling analysis in a variety of ways, including our 'Mechanism of Action program,' to study toxicological profiles of drugs, or as a step in validating our proprietary targets in therapeutic areas, such as oncology and inflammation."

Other news from the department

Most read news

More news from our other portals

Discover the latest developments in battery technology!